Functional neurological disorder (FND) Nervous System Diseases
Conditions
Interventions
The intervention consisted of two parts. The first part included the development of a collaborative biopsychosocial formulation with the participant, to help them gain a better understanding of their
Sponsors
University of Southampton
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 years and above 2. Capable of giving informed consent 3. FND diagnosis confirmed by a neurologist 4. Sufficient English to engage in therapy 5. Not currently engaged in another psychotherapy or FND treatment
Exclusion criteria
Exclusion criteria: 1. Primary diagnosis of intellectual disability 2. Severe mental ill health requiring inpatient treatment or potentially affecting trial participation (e.g., suicidality, acute psychosis, active or extensive self-harm) 3. A diagnosis of a complex regional pain syndrome, dissociative identity disorder, or posttraumatic stress disorder of high severity with significant dissociation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following questionnaires were completed at baseline, following the formulation intervention, following the ACT-based intervention and at the end of the follow-up period: 1. Quality of life (QoL) measured using the Work and Social Adjustment Scale (WSAS) 2. Emotional processing measured using the Emotional Processing Scale (EPS) 3. Psychological health measured using a 34-item Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM) 4. Psychological inflexibility measured using the Acceptance and Action Questionnaire (AAQ-II) 5. Illness perception and understanding of the condition measured using the Brief Illness Perception Questionnaire (BIPQ) | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom frequency was measured by a self-rated question “Over the last few days: (1) how often have you experienced the symptoms of your illness”. It was rated on a 10-point Likert scale ranging from 0 (no symptoms) to 10 (many severe symptoms). It was completed every 2 days throughout the length of the study. | — |
Countries
England, United Kingdom
Contacts
Public ContactIrma Konovalova
Outcome results
None listed